BIEI Stock Overview
Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Premier Biomedical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0014 |
| 52 Week High | US$0.0017 |
| 52 Week Low | US$0.0005 |
| Beta | 0 |
| 1 Month Change | 40.00% |
| 3 Month Change | 27.27% |
| 1 Year Change | 27.27% |
| 3 Year Change | -50.00% |
| 5 Year Change | -95.88% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIEI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.7% | 1.0% | 1.2% |
| 1Y | 27.3% | 0.7% | 24.9% |
Return vs Industry: BIEI exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: BIEI exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| BIEI volatility | |
|---|---|
| BIEI Average Weekly Movement | 26.3% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BIEI's share price has been volatile over the past 3 months.
Volatility Over Time: BIEI's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | n/a | www.premierbiomedical.com |
Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases. It offers pain management products comprising pain relief patch of hemp oil extracts; water-based and oil-based roll-on applicators; oil-based pump spray applicators; and ointments through its Website painreliefmeds.com and various distributors. It is also developing hemp oil products, including anti-pain patch, roll-on topical products, sprays, ointments, tincture drop product, a hemp oil capsule, and pet product; sequential-dialysis technique for cancer, Alzheimer’s disease, ALS, blood sepsis, leukemia, and other life-threatening cancers; and Feldetrex drug candidate for the treatment of multiple sclerosis, fibromyalgia, neuropathic pain, and traumatic brain injuries.
Premier Biomedical, Inc. Fundamentals Summary
| BIEI fundamental statistics | |
|---|---|
| Market cap | US$1.54m |
| Earnings (TTM) | -US$374.47k |
| Revenue (TTM) | US$14.28k |
0.0x
P/S Ratio0.0x
P/E RatioIs BIEI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIEI income statement (TTM) | |
|---|---|
| Revenue | US$14.28k |
| Cost of Revenue | US$12.86k |
| Gross Profit | US$1.42k |
| Other Expenses | US$375.89k |
| Earnings | -US$374.47k |
Last Reported Earnings
Dec 31, 2019
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did BIEI perform over the long term?
See historical performance and comparison